Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Johnson and Johnson
McKinsey
Boehringer Ingelheim
McKesson

Last Updated: March 20, 2023

Taro Pharm Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the competitive landscape for TARO PHARM, and when can generic versions of TARO PHARM drugs launch?

TARO PHARM has sixty-one approved drugs.

There are seven US patents protecting TARO PHARM drugs. There are three tentative approvals on TARO PHARM drugs.

There are twenty patent family members on TARO PHARM drugs in nine countries and fifty-six supplementary protection certificates in fourteen countries.

Summary for Taro Pharm
International Patents:20
US Patents:7
Tradenames:44
Ingredients:42
NDAs:61
Patent Litigation for Taro Pharm: See patent lawsuits for Taro Pharm

Drugs and US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds Ltd ILOPERIDONE iloperidone TABLET;ORAL 207098-007 Jul 22, 2019 DISCN No No See Plans and Pricing See Plans and Pricing
Taro Pharm Inds Ltd TOPICORT desoximetasone OINTMENT;TOPICAL 018594-001 Jan 17, 1985 AB RX Yes Yes See Plans and Pricing See Plans and Pricing
Taro Pharms CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE betamethasone dipropionate; calcipotriene SUSPENSION;TOPICAL 213269-001 Sep 2, 2020 AB RX No No See Plans and Pricing See Plans and Pricing
Taro Pharm Inds Ltd HYDROCORTISONE hydrocortisone CREAM;TOPICAL 086155-001 Approved Prior to Jan 1, 1982 DISCN No No See Plans and Pricing See Plans and Pricing
Taro Pharms Ireland ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE ondansetron hydrochloride INJECTABLE;INJECTION 078014-001 Mar 21, 2008 DISCN No No See Plans and Pricing See Plans and Pricing
Taro Pharm Inds Ltd ACETAMINOPHEN acetaminophen SUPPOSITORY;RECTAL 018337-002 Approved Prior to Jan 1, 1982 OTC Yes No See Plans and Pricing See Plans and Pricing
Taro Pharm Inds CARBAMAZEPINE carbamazepine TABLET, CHEWABLE;ORAL 075687-001 Oct 24, 2000 AB RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Taro Pharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Taro Pharms PLIAGLIS lidocaine; tetracaine CREAM;TOPICAL 021717-001 Jun 29, 2006 5,919,479 See Plans and Pricing
Taro Pharms TOPICORT desoximetasone SPRAY;TOPICAL 204141-001 Apr 11, 2013 5,990,100 See Plans and Pricing
Taro Pharms PLIAGLIS lidocaine; tetracaine CREAM;TOPICAL 021717-001 Jun 29, 2006 6,528,086 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for TARO PHARM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18

International Patents for Taro Pharm Drugs

Country Patent Number Estimated Expiration
China 101287374 See Plans and Pricing
China 102834096 See Plans and Pricing
Canada 2822220 See Plans and Pricing
European Patent Office 2523660 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2007005988 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006130510 See Plans and Pricing
European Patent Office 1888026 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Taro Pharm Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1519731 13C0067 France See Plans and Pricing PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
0463756 99C0007 Belgium See Plans and Pricing PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
2506844 1890025-8 Sweden See Plans and Pricing PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
0152897 2001C/013 Belgium See Plans and Pricing PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
0152897 SPC/GB01/012 United Kingdom See Plans and Pricing PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
1304992 PA2013025 Lithuania See Plans and Pricing PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1519731 92269 Luxembourg See Plans and Pricing PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Dow
Express Scripts
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.